Key result
Intramyocellular lipid content is ~30% higher in recent-onset type 2 diabetes compared to type 1 diabetes and controls, and remains unchanged over 5 years despite worsening insulin resistance.
Why the study?
Intramyocellular lipid content is elevated in insulin resistance, but changes over time and relationships with comorbidities remain unclear.
Cohort (n=399)
Intramyocellular lipid content is elevated in recent-onset type 2 diabetes and associates with early diabetes-related complications, including cardiovascular disease risk, but does not change over 5 years despite worsening insulin resistance.
Answers are grounded in this paper and cite their sources.
Elevated IMCL may flag early CVD risk in T2D; leaves open causal role in insulin resistance progression.
Intramyocellular lipid content (IMCL) is elevated in insulin-resistant humans, but it changes over time, and relationships with comorbidities remain unclear. We examined IMCL during the initial course of diabetes and its associations with complications. Participants of the German Diabetes Study (GDS) with recent-onset type 1 (n = 132) or type 2 diabetes (n = 139) and glucose-tolerant control subjects (n = 128) underwent 1H-MRS to measure IMCL and muscle volume, whole-body insulin sensitivity (hyperinsulinemic-euglycemic clamps; M-value), and cycling spiroergometry (VO2max). Subgroups underwent the same measurements after 5 years. At baseline, IMCL was ∼30% higher in type 2 diabetes than in other groups independently of age, sex, BMI, and muscle volume. In type 2 diabetes, the M-value was ∼36% and ∼62% lower compared with type 1 diabetes and control subjects, respectively. After 5 years, the M-value decreased by ∼29% in type 1 and ∼13% in type 2 diabetes, whereas IMCL remained unchanged. The correlation between IMCL and M-value in type 2 diabetes at baseline was modulated by VO2max. IMCL also associated with microalbuminuria, the Framingham risk score for cardiovascular disease, and cardiac autonomic neuropathy. Changes in IMCL within 5 years after diagnosis do not mirror the progression of insulin resistance in type 2 diabetes but associate with early diabetes-related complications. ARTICLE HIGHLIGHTS: Intramyocellular lipid content (IMCL) can be elevated in insulin-resistant humans, but its dynamics and association with comorbidities remain unclear. Independently of age, sex, body mass, and skeletal muscle volume, IMCL is higher in recent-onset type 2, but not type 1 diabetes, and remains unchanged within 5 years, despite worsening insulin resistance. A degree of physical fitness modulates the association between IMCL and insulin sensitivity in type 2 diabetes. Whereas higher IMCL associates with lower insulin sensitivity in people with lower physical fitness, there is no association between IMCL and insulin sensitivity in those with higher degree of physical fitness. IMCL associates with progression of microalbuminuria, cardiovascular disease risk, and cardiac autonomic neuropathy.
No takes yet. Share an insight, caveat, or question.
Schön et al. (2023) conducted a cohort in Type 1 and Type 2 Diabetes (n=399). Recent-onset type 2 diabetes vs. Type 1 diabetes and glucose-tolerant controls was evaluated on Intramyocellular lipid content (IMCL) and whole-body insulin sensitivity. Intramyocellular lipid content is ~30% higher in recent-onset type 2 diabetes compared to type 1 diabetes and controls, and remains unchanged over 5 years despite worsening insulin resistance.
Synapse has enriched 10 related papers. Consider them for comparative context: